Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chiara Lucchetti

Showing results (1-10 of 37) with videos related to

Pageof 4
Sort By:
Journal of Pediatric Surgery|April 29, 2022
OHVIRA (Obstructed Hemivagina and Ipsilateral Renal Anomaly or Herlyn-Werner-Wunderlich syndrome): Is it time for age-specific management?Angelo Zarfati, Maria Chiara Lucchetti
Journal of Pediatric and Adolescent Gynecology|July 16, 2022
First-Line Therapy for Vaginal Atresia. Conservative Treatment vs Surgical Techniques: Quandaries Looking at NumbersMaria Chiara Lucchetti, Alice Tassi
International Urogynecology Journal|July 29, 2017
Urethral prolapse in a paediatric patient with urogenital bleeding: diagnosis by imagingPaolo Tomà, Andrea Magistrelli, Maria Chiara Lucchetti
Pharmacogenomics|November 29, 2011
Research highlights. Overcoming BRAF resistance to PLX4032 by AKT inhibition in PTEN-deficient melanoma cellsChiara Lucchetti, Flavio Rizzolio, Matteo Castronovo, et al.
The International Journal of Biochemistry & Cell Biology|December 7, 2007
Genetic and epigenetic alterations in breast cancer: what are the perspectives for clinical practice?Alfredo Fucito, Chiara Lucchetti, Antonio Giordano, et al.
Pharmacogenomics|October 20, 2011
Research highlights. MCL1 and FBW7 as new predictive candidate biomarkers of anti-tubulin agentsChiara Lucchetti, Flavio Rizzolio, Matteo Castronovo, et al.
Global & Regional Health Technology Assessment|April 1, 2025
Andrea Vitagliano, Marzia Bonfanti, Chiara Lucchetti, et al.
Pharmacogenomics|November 29, 2011
Research highlights. Protein kinase D3 is the genetic sensitizer of RAF inhibitor RAF265 in melanoma cellsChiara Lucchetti, Flavio Rizzolio, Matteo Castronovo, et al.
Pharmacogenomics|November 29, 2011
Research highlights. PI3K/AKT/mTOR inhibitors would require PI3KCA-mutation analysisChiara Lucchetti, Flavio Rizzolio, Matteo Castronovo, et al.
Journal of Cellular Physiology|December 30, 2006
Transcription and epigenetic profile of the promoter, first exon and first intron of the human tyrosine hydroxylase geneGaetano Romano, Marcella Macaluso, Chiara Lucchetti, et al.
Pageof 4

Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
Journal of Pediatric Surgery|April 29, 2022
OHVIRA (Obstructed Hemivagina and Ipsilateral Renal Anomaly or Herlyn-Werner-Wunderlich syndrome): Is it time for age-specific management?Angelo Zarfati, Maria Chiara Lucchetti
Journal of Pediatric and Adolescent Gynecology|July 16, 2022
First-Line Therapy for Vaginal Atresia. Conservative Treatment vs Surgical Techniques: Quandaries Looking at NumbersMaria Chiara Lucchetti, Alice Tassi
International Urogynecology Journal|July 29, 2017
Urethral prolapse in a paediatric patient with urogenital bleeding: diagnosis by imagingPaolo Tomà, Andrea Magistrelli, Maria Chiara Lucchetti
Pharmacogenomics|November 29, 2011
Research highlights. Overcoming BRAF resistance to PLX4032 by AKT inhibition in PTEN-deficient melanoma cellsChiara Lucchetti, Flavio Rizzolio, Matteo Castronovo, et al.
The International Journal of Biochemistry & Cell Biology|December 7, 2007
Genetic and epigenetic alterations in breast cancer: what are the perspectives for clinical practice?Alfredo Fucito, Chiara Lucchetti, Antonio Giordano, et al.
Pharmacogenomics|October 20, 2011
Research highlights. MCL1 and FBW7 as new predictive candidate biomarkers of anti-tubulin agentsChiara Lucchetti, Flavio Rizzolio, Matteo Castronovo, et al.
Global & Regional Health Technology Assessment|April 1, 2025
Andrea Vitagliano, Marzia Bonfanti, Chiara Lucchetti, et al.
Pharmacogenomics|November 29, 2011
Research highlights. Protein kinase D3 is the genetic sensitizer of RAF inhibitor RAF265 in melanoma cellsChiara Lucchetti, Flavio Rizzolio, Matteo Castronovo, et al.
Pharmacogenomics|November 29, 2011
Research highlights. PI3K/AKT/mTOR inhibitors would require PI3KCA-mutation analysisChiara Lucchetti, Flavio Rizzolio, Matteo Castronovo, et al.
Journal of Cellular Physiology|December 30, 2006
Transcription and epigenetic profile of the promoter, first exon and first intron of the human tyrosine hydroxylase geneGaetano Romano, Marcella Macaluso, Chiara Lucchetti, et al.
Pageof 4